{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-002611","form_type":"8-K","ticker":"ITGR","cik":"0001114483","company_name":"Integer Holdings Corp","filed_at":"2023-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.979066+00:00","generated_at":"2026-06-16T08:08:19.472204+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Integer Q1 sales up 22% to $379M; GAAP EPS $0.39, adjusted $0.87","bullets":["Sales $379M (+22% YoY, organic +21%); GAAP net income $13M (+15%).","Non-GAAP adjusted net income $29M (+11%); adjusted diluted EPS $0.87 vs $0.78.","Adjusted EBITDA $66M (+22%); leverage ratio 3.6x; total debt $1,002M.","2023 outlook: sales $1.47B-$1.50B (7-9% growth), adjusted EPS $4.00-$4.30.","Product lines all grew: Cardio/Vascular +20%, Cardiac/Neuro +18%, Advanced Surgical/Ortho/Portable +42%, Electrochem +63%."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-002611","json":"https://secwatch.observer/filing/0001171843-23-002611.json","markdown":"https://secwatch.observer/filing/0001171843-23-002611.md","text":"https://secwatch.observer/filing/0001171843-23-002611.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1114483/000117184323002611/0001171843-23-002611-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1114483/000117184323002611/f8k_042623.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T08:08:19.472204+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4a6abeee991ec96446d5723a90b402cb1a768d5b","claim":"Integer Holdings Corp reported the three months ended March 31, 2023 results: revenue $379 million, net income $13 million, EPS $0.39 per share. Guidance reaffirmed.","evidence_excerpt":"today announced results for the three months ended March 31, 2023. First Quarter 2023 Highlights (compared to First Quarter 2022, except as noted) Sales increased 22% to $379 million, with organic growth of 21%. GAAP net income increased $2 million to $13 million, an increase of 15%. Non-GAAP adjusted net income increased $3 million to $29 million, an","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1114483/000117184323002611/0001171843-23-002611-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Revenue","value":"$379 million"},{"label":"Net income","value":"$13 million"},{"label":"EPS","value":"$0.39 per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}